Your browser doesn't support javascript.
loading
Statistical analysis plan for the NU IMPACT stepped-wedge cluster randomized trial.
Scholtens, Denise M; Lancki, Nicola; Hemming, Karla; Cella, David; Smith, Justin D.
Affiliation
  • Scholtens DM; Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States of America. Electronic address: dscholtens@northwestern.edu.
  • Lancki N; Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States of America.
  • Hemming K; Institute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom.
  • Cella D; Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, United States of America; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, United States of America.
  • Smith JD; Department of Population Health Sciences, University of Utah Spencer Fox Eccles School of Medicine, Salt Lake City, UT, United States of America.
Contemp Clin Trials ; 143: 107603, 2024 Aug.
Article in En | MEDLINE | ID: mdl-38852769
ABSTRACT

BACKGROUND:

As part of the IMPACT Consortium of three effectiveness-implementation trials, the NU IMPACT trial was designed to evaluate implementation and effectiveness outcomes for an electronic health record (EHR)-embedded symptom monitoring and management program for outpatient cancer care. NU IMPACT uses a unique stepped-wedge cluster randomized design, involving six clusters of 26 clinics, for evaluation of implementation outcomes with an embedded patient-level randomized trial to evaluate effectiveness outcomes. Collaborative, consortium-wide efforts to ensure use of the most robust and recent analytic methodologies for stepped-wedge trials motivated updates to the statistical analysis plan for implementation outcomes in the NU IMPACT trial.

METHODS:

In the updated statistical analysis plan for NU IMPACT, the primary implementation outcome patient adoption, as measured by clinic-level monthly proportions of patient engagement with the EHR-based cancer symptom monitoring system, will be analyzed using generalized least squares linear regression with auto-regressive errors and adjustment for cluster and time effects (underlying secular trends). A similar strategy will be used for secondary patient and provider implementation outcomes.

DISCUSSION:

The analytic updates described here resulted from highly iterative, collaborative efforts among statisticians, implementation scientists, and trial leads in the IMPACT Consortium. This updated statistical analysis plan will serve as the a priori specified approach for analyzing implementation outcomes for the NU IMPACT trial.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Electronic Health Records / Neoplasms Limits: Humans Language: En Journal: Contemp Clin Trials Journal subject: MEDICINA / TERAPEUTICA Year: 2024 Document type: Article Publication country: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Electronic Health Records / Neoplasms Limits: Humans Language: En Journal: Contemp Clin Trials Journal subject: MEDICINA / TERAPEUTICA Year: 2024 Document type: Article Publication country: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA